CLVT · Clarivate Plc

Clarivate Plc reported a solid start to fiscal 2026, demonstrating tangible progress on its Value Creation Plan (VCP) launched in early 2025. While total revenues declined 1.4% year-over-year to $585.5 million due to the impact of inorganic disposals, organic revenue improved 0.6%, driven by 1.7% organic subscription growth. This shift underscores management's strategic focus on transitioning toward a more stable, subscription-led revenue base. The Intellectual Property segment showed particular strength, with organic ACV growth approaching flat performance, while the Academia & Government segment delivered organic subscription revenue growth greater than 2%.

Profitability metrics improved significantly during the quarter. Adjusted EBITDA increased 3.4% to $241.2 million, resulting in a 190 basis point expansion in Adjusted EBITDA margin to 41.2%. This margin expansion was driven by operational efficiencies and the benefits of the company's business model optimization. The company also utilized its strong free cash flow generation of $78.9 million to strengthen its balance sheet, retiring $143.1 million of debt and repurchasing $18 million of ordinary shares. These actions align with management's capital allocation priorities of deleveraging and returning capital to shareholders.

Looking forward, management reaffirmed its full-year 2026 financial outlook, projecting Adjusted EBITDA in the range of $980 million to $1.04 billion and Free Cash Flow between $365 million and $435 million. The company also announced a strategic initiative to pursue the sale of its Life Sciences & Healthcare (LS&H) business, a move intended to rationalize the portfolio and increase execution focus. Management noted that the LS&H sale process is ongoing with due diligence progressing, though there is no guarantee of an agreement. The successful execution of the VCP and the potential divestiture of the LS&H segment are key catalysts for unlocking shareholder value.